Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Viking Experimental Obesity Pill Shows Promise in Early Study
Viking Therapeutics Inc. said higher doses of its experimental pill increased patients’ weight loss beyond earlier formulations, strengthening its case to eventually compete with blockbuster shots from Novo Nordisk A/S and Eli Lilly & Co.
AstraZeneca says experimental obesity pill safe and tolerable in early-stage trial
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class. The Phase I trial - which had 72 participants - was designed to assess the safety and tolerability of the pill,
Viking Therapeutics stock jumps after weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics stock soared 21% in early trade Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The study of VK2735 amo
Viking Obesity Pill Data Shows Promise Against Shots
Yes, a Viking drug So it's a dual agonist of oral gel or an oral drug, GLP one and GLP essentially targeting two receptors. And yeah, I guess it was one of the most eagerly awaited kind of data set that was conference on that.
Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
FierceBiotech1d
Viking oral obesity med posts 6.8% weight loss for highest dose
The biotech had tested the oral asset, dubbed VK2735, at doses ranging from 2.5 mg up to 100 mg. Viking already revealed back in March that 25% of the eight patients who received 20-mg doses saw their ...
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
This High-Flying Stock Just Became a Better Buy
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...
Zacks.com on MSN20d
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know
Viking Therapeutics, Inc. (VKTX) closed at $65.85 in the latest trading session, marking a +0.72% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. On the ...
bovnews19d
Viking Therapeutics Inc (VKTX) Stock: More Strategic Than Meets the Eye
On Wednesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $65.85 which represents a slight increase of $0.47 or 0.72% from the prior close of $65.38. The stock opened ...
Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future
Shares of pharmaceutical upstart Viking Therapeutics (NASDAQ: VKTX) have been soaring this year thanks to high hopes for VK2735, its promising GLP-1 weight loss treatment. Althoug ...
Viking Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...